Ten adults were treated with ketogenic diet monotherapy for epilepsy. Four patients were naïve to antiseizure drugs(ASD) and six previously tried and stopped ASDs. Of four treatment-naïve participants, two(50%) were free from disabling seizures on Modified Atkins Diet(MAD) monotherapy for > one year. Two(50%) stopped. Four of six patients(67%) who had previously tried ASDs became seizure-free on diet monotherapy and two experienced > 50% seizure reduction. Side effects included amenorrhea, weight loss, osteoporosis, and hyperlipidemia. Diet monotherapy may be feasible, well-tolerated, and effective for adults with epilepsy who refuse pharmacotherapy and those for whom lifelong diet therapy is recommended.
INTRODUCTION
Initial antiseizure drug monotherapy controls seizures in approximately half of patients with newly-diagnosed epilepsy. Remission rates range from 63-84% in patients with focal epilepsy on monotherapy with 5 of the most common antiseizure drugs [1] . However, long-term retention is low due to side effects, ranging from 32-58% after 3 years [1] . Ketogenic diets are effective in approximately half of patients with antiseizure drug-resistant epilepsy [2] [3] [4] . The Classic Ketogenic Diet (KD; composed of a 4:1 ratio of grams of fat: carbohydrates and protein combined) is used in unique circumstances first-line or as monotherapy, for instance in patients with infantile spasms, Glucose Transporter Type 1 (GLUT1) deficiency syndrome, and children on ketogenic diets alone after seizures are controlled and antiseizure drugs have been successfully weaned [5, 6] .
Use of KD in adults is limited by restrictiveness [7] . Studies have shown successful compliance with a Modified Atkins Diet (MAD) [8, 9] , which also produces urine and serum ketones but without hospital admission, weighing foods, or calorie calculation [7] . As a result, epilepsy centers are beginning to offer MAD to adults [10] .
Demand for access to ketogenic diets is increasing in adults with newly-diagnosed epilepsy wishing to avoid antiseizure drugs, patients who have experienced adverse effects from antiseizure drugs and stopped, and patients that require lifelong antiseizure treatment. The purpose of this study is to identify circumstances in which ketogenic diets are used first-line or as monotherapy to control seizures in adults.
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MATERIALS AND METHODS
Adults (age ≥ 18 years) evaluated in the Johns Hopkins Adult Epilepsy Diet Center (AEDC) [10] from August 2010 to August 2016 were followed with written informed consent obtained from the patient or a legally authorized representative. Individuals with newlydiagnosed epilepsy (two or more unprovoked seizures or one seizure and an EEG that captured epileptiform activity) that chose to avoid pharmacotherapy and adults with a history of uncontrolled epilepsy who tried and stopped all antiseizure drugs prior to the initial visit were assessed. Patients who were seizure-free for 1 year or more on no antiseizure drugs before starting diet therapy were excluded. Seizure classification was made using the current International League Against Epilepsy classification system and review of EEG and clinical data [11] . Baseline pre-diet seizure frequency was determined based on review of records in patients already on a ketogenic diet prior to the initial visit and by reviewing seizure calendars for 1 or more moths prior to diet initiation for patients beginning a ketogenic diet de novo.
One participant on a 3:1 ratio ketogenic diet prior to the initial visit remained on the same ratio for the duration of the study. All other participants were prescribed a 20 gram per day net carbohydrate limit MAD. All participants recorded urine ketone body production (goal acetoacetate ≥ 40 mg/dL) biweekly, seizure frequency daily, and weights weekly [10] . Seizure frequency, diet compliance, side effects, and routine laboratory studies were assessed at 3-6 month intervals during routine outpatient visits.
Descriptive statistics were used to present patient characteristics and treatment outcomes.
Proportions were calculated of all categorical variables and means, medians, ranges, and standard deviations were calculated for continuous variables as appropriate.
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RESULTS
Of 201 consented participants, 10 were on no antiseizure drugs at the time of the initial visit and met inclusion criteria (Table 1) . Four participants were naive to antiseizure drugs (all female, ages 19-86 years at the time of the initial visit, median 38 years). Six participants had previously tried one or more antiseizure drugs and stopped prior to the initial visit (3 female, age 18-52 years at the initial visit). Of the four treatment-naïve participants ( Table 2 
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DISCUSSION
Approximately half of patients with newly-diagnosed epilepsy respond to the first antiseizure drug tried [12] . Long-term retention rates are low, likely due to adverse effects [1] . As a result, a subset seek alternatives to antiseizure drugs, of which ketogenic diets such as the Classic Ketogenic Diet or the Modified Atkins Diet may be a reasonable option. Two patient populations were studied, adults treated with MAD first-line and those that had tried one or more antiseizure drugs previously but stopped, using diet therapy as an alternative. Both populations showed surprisingly good outcomes. Half of patients that tried MAD first-line remained free from disabling seizures following a year or more of diet monotherapy and half stopped due to difficulty complying with the carbohydrate restriction and increased fat requirements. Two thirds of patients that used ketogenic diet therapy as an alternative to additional antiseizure drug trials became seizure-free, and two had an 88% or greater seizure reduction. Average diet duration was over 4 years. Four patients have been granted driving privileges.
Two patients that became seizure-free on MAD carry the diagnosis of genetic generalized epilepsy (juvenile absence epilepsy or juvenile myoclonic epilepsy). Prior studies have demonstrated efficacy of the MAD in this patient population [13, 14] . Three patients in these prior publications were on MAD monotherapy and none achieved seizure freedom (two stopped MAD due to lack of motivation and one experienced a 90% reduction in seizure frequency), so these new findings are encouraging. To our knowledge, this is the first study to report control of focal-onset epilepsy in adults on MAD monotherapy, which was achieved in half of participants with focal epilepsy that were compliant on MAD. One participant had an underlying primary brain tumor and preliminary studies show that MAD may be beneficial in this population [15] .
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Side effects included amenorrhea, hyperlipidemia, osteoporosis, and intentional weight loss. The complex interactions between hormones and ketone production are not well understood and warrant further investigation. Hyperlipidemia may be reduced by limiting or eliminating heavy cream and decreasing the fat ratio of the ketogenic diet. Early vitamin D and calcium supplementation may reduce the risk of osteoporosis.
Patients in this study were self-selected and highly motivated, likely introducing bias into the cohort, which is a study limitation. Baseline seizure frequency was obtained retrospectively, based on 1 month pre-diet self-report, and may have led to an inaccurate determination of diet response. Two patients had normal diagnostic studies but clinical history highly suggestive of focal epilepsy, and nonepileptic events cannot be excluded. In addition, two participants had an underlying diagnosis of GLUT1 deficiency syndrome, for which ketogenic diets are known to be the preferred treatment and highly successful in controlling seizures, further biasing the efficacy results. When excluding these patients from further analysis, 2 of 6 (33%) of the remaining participants became seizure-free on MAD and 2 of 6 (33%) stopped diet therapy, while the remaining 2 of 6 (33%) had a greater than 50% seizure reduction. These findings argue that diet monotherapy may be of benefit in adult epilepsy but studies with larger patient populations are needed to confirm this.
CONCLUSIONS
In conclusion, for adults with new-onset epilepsy who are resistant to trying antiseizure medications or have experienced intolerable side effects, a diet may be a feasible, well-tolerated (provided that appropriate measures are taken to prevent side effects), and effective alternative long-term. Prospective, randomized trials comparing diets to first-line antiseizure drug treatment are necessary to determine the comparative efficacy, treatment retention, and adverse effects. atonic seizures h tonic seizures JAE = juvenile absence epilepsy, JME = juvenile myoclonic epilepsy, TBI = traumatic brain injury, GLUT1 = Glucose Transporter Type 1 deficiency syndrome, MAD = Modified Atkins Diet, KD = Ketogenic Diet *on a strict ketogenic diet prior to initial visit to Johns Hopkins Adult Epilepsy Diet Center **only residual seizures were paresthesias without alteration of consciousness or awareness
